How much revenue did Sesen Bio generate this year?
Sesen Bio has achieved a revenue of 0 USD this year.
Sesen Bio Revenue 2024
Sesen Bio Revenue
0 USD
Ticker
SESN
ISIN
US8177631053
WKN
A2JL47
In 2024, Sesen Bio's sales reached 0 USD, a 0% difference from the 0 USD sales recorded in the previous year.
The Sesen Bio Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2028e | - | - |
| 2027e | - | - |
| 2026e | - | - |
| 2025e | - | - |
| 2024e | - | - |
| 2023e | - | - |
| 2022 | 40 | - |
| 2021 | 26.54 | - |
| 2020 | 11.24 | - |
| 2019 | - | - |
| 2018 | - | - |
| 2017 | 0.43 | - |
| 2016 | 29.98 | - |
| 2015 | 0.99 | - |
| 2014 | 2.24 | - |
| 2013 | 1.33 | - |
| 2012 | - | - |
| 2011 | - | - |
Sesen Bio Revenue, EBIT, Net Income US8177631053 · A2JL47
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Sesen Bio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sesen Bio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sesen Bio’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Sesen Bio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Sesen Bio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Sesen Bio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sesen Bio’s growth potential.
Sesen Bio Revenue, EBIT and net profit per share
| Date | Sesen Bio Revenue | Sesen Bio EBIT | Sesen Bio Net Income |
|---|---|---|---|
| 2028e | 0 undefined | 0 undefined | -4.07 M undefined |
| 2027e | 0 undefined | -8.06 M undefined | -4.07 M undefined |
| 2026e | 0 undefined | -7.75 M undefined | -4.07 M undefined |
| 2025e | 0 undefined | -7.14 M undefined | -4.07 M undefined |
| 2024e | 0 undefined | -6.63 M undefined | -6.1 M undefined |
| 2023e | 0 undefined | -16.63 M undefined | -18.31 M undefined |
| 2022 | 40 M undefined | 13.62 M undefined | -19.88 M undefined |
| 2021 | 26.54 M undefined | 28.68 M undefined | -336,000 undefined |
| 2020 | 11.24 M undefined | -21.08 M undefined | -22.54 M undefined |
| 2019 | 0 undefined | -108.49 M undefined | -107.5 M undefined |
| 2018 | 0 undefined | -34.5 M undefined | -33.69 M undefined |
| 2017 | 425,000 undefined | -29.26 M undefined | -29.03 M undefined |
| 2016 | 29.98 M undefined | 2.87 M undefined | 1.89 M undefined |
| 2015 | 990,000 undefined | -35.2 M undefined | -33.45 M undefined |
| 2014 | 2.24 M undefined | -32.93 M undefined | -34.16 M undefined |
| 2013 | 1.33 M undefined | -16.2 M undefined | -18.03 M undefined |
| 2012 | 0 undefined | -19.48 M undefined | -19.66 M undefined |
| 2011 | 0 undefined | -12.68 M undefined | -12.83 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2011 | 0 USD | -12.68 M USD | -12.83 M USD |
| 2012 | 0 USD | -19.48 M USD | -19.66 M USD |
| 2013 | 1.33 M USD | -16.2 M USD | -18.03 M USD |
| 2014 | 2.24 M USD | -32.93 M USD | -34.16 M USD |
| 2015 | 990,000 USD | -35.2 M USD | -33.45 M USD |
| 2016 | 29.98 M USD | 2.87 M USD | 1.89 M USD |
| 2017 | 425,000 USD | -29.26 M USD | -29.03 M USD |
| 2018 | 0 USD | -34.5 M USD | -33.69 M USD |
| 2019 | 0 USD | -108.49 M USD | -107.5 M USD |
| 2020 | 11.24 M USD | -21.08 M USD | -22.54 M USD |
| 2021 | 26.54 M USD | 28.68 M USD | -336,000 USD |
| 2022 | 40 M USD | 13.62 M USD | -19.88 M USD |
| 2023e | 0 USD | -16.63 M USD | -18.31 M USD |
| 2024e | 0 USD | -6.63 M USD | -6.1 M USD |
| 2025e | 0 USD | -7.14 M USD | -4.07 M USD |
| 2026e | 0 USD | -7.75 M USD | -4.07 M USD |
| 2027e | 0 USD | -8.06 M USD | -4.07 M USD |
| 2028e | 0 USD | 0 USD | -4.07 M USD |
Sesen Bio stock margins US8177631053 · A2JL47
The Sesen Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sesen Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sesen Bio.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Sesen Bio's sales revenue. A higher gross margin percentage indicates that the Sesen Bio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Sesen Bio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Sesen Bio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sesen Bio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sesen Bio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sesen Bio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Sesen Bio Margin History
| Sesen Bio Gross margin | Sesen Bio Profit margin | Sesen Bio EBIT margin | Sesen Bio Profit margin |
|---|---|---|---|
| 2028e | 0 % | 0 % | 0 % |
| 2027e | 0 % | 0 % | 0 % |
| 2026e | 0 % | 0 % | 0 % |
| 2025e | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
| 2023e | 0 % | 0 % | 0 % |
| 2022 | 0 % | 34.05 % | -49.71 % |
| 2021 | 0 % | 108.04 % | -1.27 % |
| 2020 | 0 % | -187.58 % | -200.64 % |
| 2019 | 0 % | 0 % | 0 % |
| 2018 | 0 % | 0 % | 0 % |
| 2017 | 0 % | -6,883.53 % | -6,830.35 % |
| 2016 | 0 % | 9.57 % | 6.3 % |
| 2015 | 0 % | -3,555.56 % | -3,378.79 % |
| 2014 | 0 % | -1,470.09 % | -1,525 % |
| 2013 | 0 % | -1,218.05 % | -1,355.64 % |
| 2012 | 0 % | 0 % | 0 % |
| 2011 | 0 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2011 | 0 % | 0 % | 0 % |
| 2012 | 0 % | 0 % | 0 % |
| 2013 | 0 % | -1,218.05 % | -1,355.64 % |
| 2014 | 0 % | -1,470.09 % | -1,525 % |
| 2015 | 0 % | -3,555.56 % | -3,378.79 % |
| 2016 | 0 % | 9.57 % | 6.3 % |
| 2017 | 0 % | -6,883.53 % | -6,830.35 % |
| 2018 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2020 | 0 % | -187.58 % | -200.64 % |
| 2021 | 0 % | 108.04 % | -1.27 % |
| 2022 | 0 % | 34.05 % | -49.71 % |
| 2023e | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
| 2025e | 0 % | 0 % | 0 % |
| 2026e | 0 % | 0 % | 0 % |
| 2027e | 0 % | 0 % | 0 % |
| 2028e | 0 % | 0 % | 0 % |
Sesen Bio Aktienanalyse
What does Sesen Bio do?
Sesen Bio Inc. is a biotechnology company focused on developing advanced therapeutics for the treatment of cancer and other challenging diseases. The company was founded in 2010 in Cambridge, Massachusetts, and has since expanded its research and development efforts to develop a range of therapies based on its innovative technologies and approaches. The goal of Sesen Bio is to develop groundbreaking drugs and therapies that are both safe and effective, helping patients successfully fight their illness. The company's focus is on unlocking new treatment possibilities through its proprietary platforms, including its antibody-drug conjugate (ADC) technology, on which all drug candidates are based. Sesen Bio has three main divisions: cancer treatment, therapy development, and partnership program. The cancer treatment division focuses on clinical trials and product marketing. This is where the first approved drug, Vicinium, is mentioned. Vicinium is an ADC consisting of a monoclonal antibody against prostate-specific membrane antigen (PSMA). It is indicated for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapy development division is involved in creating drug candidates and advancing their development through clinical trials. The partnership program allows Sesen Bio to license and commercialize its technologies and platforms by partnering with other biotechnology companies and pharmaceutical companies. The company has made significant progress in the development of therapeutics in recent years. The first approved drug, Vicinium, has propelled the company forward. The company is conducting clinical trials on other drug candidates to evaluate their efficacy and safety. Additionally, the company has a pipeline of new products in various stages of development, including NG-348, a novel ADC targeting the epidermal growth factor receptor (EGFR) that can be used in the treatment of solid tumors in various organs. Sesen Bio aims to further expand its innovative technologies in the field of cancer therapy and expand its offering of groundbreaking therapeutics. The company works closely with its partners and customers to develop customized treatment solutions and ensure high patient satisfaction. With its dedicated research and development department, well-established partnerships, and ability to make groundbreaking technologies widely available, Sesen Bio is on track to become a leading company in the field of cancer therapy. Overall, Sesen Bio is an innovative biotechnology company dedicated to developing therapeutics that improve the lives of patients with cancer and other serious diseases. Through its proprietary technologies and platforms, dedicated research and development departments, and well-established partnerships, the company has established itself as a key player in the field of cancer therapy. Sesen Bio is a company with a vision and a mission that permeate everything it does, namely saving and improving lives. Sesen Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Sesen Bio's Sales Figures
The sales figures of Sesen Bio originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Sesen Bio’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Sesen Bio's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Sesen Bio’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Sesen Bio stock
How much was the turnover of the company Sesen Bio compared to the previous year?
The revenue of Sesen Bio has increased by 0% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Sesen Bio?
The revenue of Sesen Bio is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Sesen Bio measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Sesen Bio so important for investors?
The revenue of Sesen Bio is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Sesen Bio pay?
Over the past 12 months, Sesen Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sesen Bio is expected to pay a dividend of 0 USD.
What is the dividend yield of Sesen Bio?
The current dividend yield of Sesen Bio is .
When does Sesen Bio pay dividends?
Sesen Bio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Sesen Bio?
Sesen Bio paid dividends every year for the past 0 years.
What is the dividend of Sesen Bio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Sesen Bio located?
Sesen Bio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Sesen Bio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Sesen Bio from 8/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/2/2024.
When did Sesen Bio pay the last dividend?
The last dividend was paid out on 8/2/2024.
What was the dividend of Sesen Bio in the year 2023?
In the year 2023, Sesen Bio distributed 0 USD as dividends.
In which currency does Sesen Bio pay out the dividend?
The dividends of Sesen Bio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Sesen Bio stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Sesen Bio
Our stock analysis for Sesen Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sesen Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
